Replies to post #232 on Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

Based on the ASCO abstracts, AP534 appears to be far more effective than bosutinib. In CP pts who have failed 2 tki's(imatinib and dasatinib), bosutinib achieved a 42% MCyR.

In the data released today, AP534 achieved a 48% MCyR BUT the Ariad trial included pts in both the advanced and blast phase's of the disease while the bosutinib trial only included pts in the chronic phase. Bottomline - AP534 achieved a higher MCyR than bosutinib in a sicker patient population.

http://abstract.asco.org/AbstView_74_52695.html

[Au-530]

Data on ARIAD's Oncology Pipeline to Be Presented at the 2010 ASCO Annual MeetingLast update: 5/21/2010 7:35:00 AMCAMBRIDGE, Mass., May 21, 2010 (BUSINESS WIRE) -- ARIAD Pharmaceuticals, Inc. (ARIA) today announced that new data on AP24534, its investigational pan-BCR-ABL inhibitor, and ridaforolimus, its investigational mTOR inhibitor being developed by Merck, Sharpe & Dohme Corp., have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois being held June 4 to 8, 2010. The schedule and meeting location for the sessions, together with the abstract information, are listed below by program: AP24534 Title: Phase 1 trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and other hematologic malignancies Date & Time: Monday, June 7, 2010, 2:00 PM -- 6:00 PM (with presentation at 5:00 PM) Abstract: #53232 Presenter: Moshe Talpaz, M.D. (University of Michigan) Location: Exhibit Hall, 354a Ridaforolimus Title: A phase 1 study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotuzumab (DALO) in patients (pts) with advanced solid tumors Date & Time: Saturday, June 5, 2010, 1:30 PM - 2:00 PM Abstract: #48347 Presenter: Serena Di Cosimo, M.D. (Breast Cancer Center, Vall d'Hebron University Hospital) Location: Exhibit Hall, D2 Title: A multi-center, first-in-pediatrics phase 1 study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors Date & Time: Sunday, June 6, 2010, 5:00 PM -- 6:00 PM Abstract: #48828 Presenter: Lia Gore, M.D. (University of Colorado Denver and The Children's Hospital) Location: Room S 504 About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need -- aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck, Sharpe & Dohme Corp. and is in Phase 3 clinical development in patients with advanced sarcomas. ARIAD's second internally discovered product candidate, AP24534, is an investigational pan-BCR-ABL inhibitor completing Phase 1 clinical development in patients with hematological cancers, notably chronic myeloid leukemia. For additional information about the Company, please visit . SOURCE: ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc. Maria E. Cantor, 617-621-2208Copyright Business Wire 2010